The potential use of plasma NfL as a diagnostic and prognostic biomarker of fatigue in early Parkinson's disease.

ABSTRACT:

Background

Fatigue is a prevalent non-motor symptom that often appears in the early stages of Parkinson's disease (PD). Plasma neurofilament light chain (NfL) was elevated in PD patients and may be considered a potential biomarker for both motor and cognitive progression.

Objectives

In this study, we explored the association between plasma NfL levels and various fatigue subtypes and the prediction of baseline plasma NfL levels for fatigue subtype conversion.

Methods

Patients with PD were classified into four categories: persistent fatigue, never fatigue, non-persistent fatigue, and new-onset fatigue. They underwent detailed neurological evaluations at baseline and a 2-year follow-up. Plasma NfL, glial fibrillary acidic protein, phosphorylated tau181, amyloid beta 42,

SUBMITTER: Che N 

PROVIDER: S-EPMC11912176 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature